A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Clinical trial NCT06448312 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06448312
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-07
- Primary completion
- 2026-11-01
- Enrollment
- 406
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.